Amphastar Pharmaceuticals Research and Development Expenses 2012-2024 | AMPH

Amphastar Pharmaceuticals research and development expenses from 2012 to 2024. Research and development expenses can be defined as an expense arising from studies and product development processes.
Amphastar Pharmaceuticals Annual Research and Development Expenses
(Millions of US $)
2023 $74
2022 $75
2021 $61
2020 $67
2019 $69
2018 $58
2017 $44
2016 $42
2015 $37
2014 $29
2013 $33
2012 $31
2011 $31
2009 $
Amphastar Pharmaceuticals Quarterly Research and Development Expenses
(Millions of US $)
2024-09-30 $21
2024-06-30 $18
2024-03-31 $17
2023-12-31 $20
2023-09-30 $17
2023-06-30 $17
2023-03-31 $20
2022-12-31 $17
2022-09-30 $19
2022-06-30 $23
2022-03-31 $16
2021-12-31 $17
2021-09-30 $11
2021-06-30 $18
2021-03-31 $15
2020-12-31 $18
2020-09-30 $18
2020-06-30 $16
2020-03-31 $15
2019-12-31 $20
2019-09-30 $19
2019-06-30 $16
2019-03-31 $15
2018-12-31 $17
2018-09-30 $11
2018-06-30 $15
2018-03-31 $14
2017-12-31 $11
2017-09-30 $10
2017-06-30 $11
2017-03-31 $11
2016-12-31 $13
2016-09-30 $10
2016-06-30 $11
2016-03-31 $9
2015-12-31 $9
2015-09-30 $11
2015-06-30 $11
2015-03-31 $7
2014-12-31 $8
2014-09-30 $9
2014-06-30 $6
2014-03-31 $6
2013-12-31 $7
2013-09-30 $9
2013-06-30 $8
2013-03-31 $9
2012-12-31
2012-09-30
2012-06-30
2012-03-31
2011-12-31
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $2.097B $0.644B
Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable and inhalation products. The company products include Enoxaparin Sodium Injection; Amphadase; Cortrosyn for Injection; and prefilled disposable emergency syringes for crash cart use. Amphastar Pharmaceuticals, Inc. is headquartered in Rancho Cucamonga, California.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.044B 6.25
Dr Reddy's Laboratories (RDY) India $11.978B 22.92
BridgeBio Pharma (BBIO) United States $4.260B 0.00
Bausch Health Cos (BHC) Canada $3.012B 2.18
Supernus Pharmaceuticals (SUPN) United States $1.962B 26.71
Taysha Gene Therapies (TSHA) United States $0.434B 30.29
Personalis (PSNL) United States $0.261B 0.00
Assembly Biosciences (ASMB) United States $0.098B 0.00
Sol-Gel Technologies (SLGL) Israel $0.012B 0.00
Evoke Pharma (EVOK) United States $0.007B 0.00
Teligent (TLGT) United States $0.000B 0.00